Type i interferons in regulation of mucosal immunity

Immunology and Cell Biology

Volumn 90, Issue 5, 2012, Pages 510-519

  Mangan, Niamh E ^a   Fung, Ka Yee ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

immune response; mucosal immunity; Type I interferons

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CIGARETTE SMOKE; INTERFERON; INTERLEUKIN 15; PATTERN RECOGNITION RECEPTOR; STAT1 PROTEIN; TOLL LIKE RECEPTOR;

B LYMPHOCYTE; CD4+ T LYMPHOCYTE; DOWNSTREAM PROCESSING; GASTROINTESTINAL TRACT; GENITAL SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; INNATE IMMUNITY; INTERFERON INDUCTION; INTERFERON PRODUCTION; LYMPHOCYTE ACTIVATION; MACROPHAGE; MOLECULAR RECOGNITION; MUCOSA CELL; MUCOSAL IMMUNITY; NONHUMAN; PARAINFLUENZA VIRUS INFECTION; PATHOGENESIS; RESPIRATORY SYSTEM; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; VACCINATION; VIRUS INFECTION; VIRUS REPLICATION;

ANIMALS; HOMEOSTASIS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, MUCOSAL; IMMUNOMODULATION; INTERFERON TYPE I; METAGENOME; MUCOUS MEMBRANE;

EID: 84861665958     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2012.13     Document Type: Review

References (139)

1. Beaurepaire C, Smyth D, McKay DM. Interferon-gamma regulation of intestinal epithelial permeability. J Interferon Cytokine Res 2009; 29: 133-144.
2. Kotenko SV. IFN-lambdas. Curr Opin Immunol 2011; 23: 583-590.
3. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005; 11(4 Suppl): S45-S53.
4. Noppert SJ, Fitzgerald KA, Hertzog PJ. The role of type I interferons in TLR responses. Immunol Cell Biol 2007; 85: 446-457.
5. Thomas C, Moraga I, Levin D, Krutzik PO, Podoplelova Y, Trejo A et al. Structural linkage between ligand discrimination and receptor activation by type I interferons. Cell 2011; 146: 621-632.
6. Samarajiwa SA, Forster S, Auchettl K, Hertzog PJ. INTERFEROME: the database of interferon regulated genes. Nucleic Acids Res 2009; 37(Database issue): D852-D857.
7. Hertzog P, Forster S, Samarajiwa S. Systems biology of interferon responses. J Interferon Cytokine Res 2011; 31: 5-11.
8. Pickert G, Neufert C, Leppkes M, Zheng Y, Wittkopf N, Warntjen M et al. STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J Exp Med 2009; 206: 1465-1472.
9. Meraz MA, White JM, Sheehan KC, Bach EA, Rodig SJ, Dighe AS et al. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 1996; 84: 431-442.
10. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 2011; 472: 481-485.
11. Pierik M, Joossens S, Van Steen K, Van Schuerbeek N, Vlietinck R, Rutgeerts P et al. Toll-like receptor-1, -2, and -6 polymorphisms influence disease extension in inflammatory bowel diseases. Inflamm Bowel Dis 2006; 12: 1-8.
12. Vijay-Kumar M, Sanders CJ, Taylor RT, Kumar A, Aitken JD, Sitaraman SV et al. Deletion of TLR5 results in spontaneous colitis in mice. J Clin Invest 2007; 117: 3909-3921.
13. Obermeier F, Dunger N, Strauch UG, Hofmann C, Bleich A, Grunwald N et al. CpG motifs of bacterial DNA essentially contribute to the perpetuation of chronic intestinal inflammation. Gastroenterology 2005; 129: 913-927.
14. Kurt-Jones EA, Popova L, Kwinn L, Haynes LM, Jones LP, Tripp RA et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 2000; 1: 398-401.
15. Sato A, Linehan MM, Iwasaki A. Dual recognition of herpes simplex viruses by TLR2 and TLR9 in dendritic cells. Proc Natl Acad Sci USA 2006; 103: 17343-17348.
16. Rasmussen SB, Jensen SB, Nielsen C, Quartin E, Kato H, Chen ZJ et al. Herpes simplex virus infection is sensed by both Toll-like receptors and retinoic acidinducible gene-like receptors, which synergize to induce type I interferon production. J Gen Virol 2009; 90(Pt 1): 74-78.
17. Melchjorsen J, Rintahaka J, Soby S, Horan KA, Poltajainen A, Ostergaard L et al. Early innate recognition of herpes simplex virus in human primary macrophages is mediated via the MDA5/MAVS-dependent and MDA5/MAVS/RNA polymerase IIIindependent pathways. J Virol 2010; 84: 11350-11358.
18. Conrady CD, Zheng M, Fitzgerald KA, Liu C, Carr DJ. Resistance to HSV-1 infection in the epithelium resides with the novel innate sensor, IFI-16. Mucosal Immunol 2012; 5: 173-183.
19. Barreau F, Meinzer U, Chareyre F, Berrebi D, Niwa-Kawakita M, Dussaillant M et al. CARD15/NOD2 is required for Peyer's patches homeostasis in mice. PLoS One 2007; 2: e523.
20. Hisamatsu T, Suzuki M, Reinecker HC, Nadeau WJ, McCormick BA, Podolsky DK. CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology 2003; 124: 993-1000.
21. Pandey AK, Yang Y, Jiang Z, Fortune SM, Coulombe F, Behr MA et al. NOD2, RIP2 and IRF5 play a critical role in the type I interferon response to Mycobacterium tuberculosis. PLoS Pathog 2009; 5: e1000500.
22. Prantner D, Darville T, Nagarajan UM. Stimulator of IFN gene is critical for induction of IFN-βeta during Chlamydia muridarum infection. J Immunol 2010; 184: 2551-2560.
23. Grubman A, Kaparakis M, Viala J, Allison C, Badea L, Karrar A et al. The innate immune molecule, NOD1, regulates direct killing of Helicobacter pylori by antimicrobial peptides. Cell Microbiol 2010; 12: 626-639.
24. Watanabe T, Asano N, Fichtner-Feigl S, Gorelick PL, Tsuji Y, Matsumoto Y et al. NOD1 contributes to mouse host defense against Helicobacter pylori via induction of type I IFN and activation of the ISGF3 signaling pathway. J Clin Invest 2010; 120: 1645-1662.
25. Watanabe T, Asano N, Kitani A, Fuss IJ, Chiba T, Strober W. Activation of type I IFN signaling by NOD1 mediates mucosal host defense against Helicobacter pylori infection. Gut Microbes 2011; 2: 61-65.
26. Slater L, Bartlett NW, Haas JJ, Zhu J, Message SD, Walton RP et al. Co-ordinated role of TLR3, RIG-I and MDA5 in the innate response to rhinovirus in bronchial epithelium. PLoS Pathog 2010; 6: e1001178.
27. Lelouard H, Fallet M, de Bovis B, Meresse S, Gorvel JP. Peyer's patch dendritic cells sample antigens by extending dendrites through M cell-specific transcellular pores. Gastroenterology 2011; 142: 592-601. e3.
28. Parker D, Martin FJ, Soong G, Harfenist BS, Aguilar JL, Ratner AJ et al. Streptococcus pneumoniae DNA initiates type I interferon signaling in the respiratory tract. MBio 2011; 2: e00016-11.
29. Jung A, Kato H, Kumagai Y, Kumar H, Kawai T, Takeuchi O et al. Lymphocytoid choriomeningitis virus activates plasmacytoid dendritic cells and induces a cytotoxic T-cell response via MyD88. J Virol 2008; 82: 196-206.
30. Kumagai Y, Takeuchi O, Kato H, Kumar H, Matsui K, Morii E et al. Alveolar macrophages are the primary interferon-alpha producer in pulmonary infection with RNA viruses. Immunity 2007; 27: 240-252.
31. Lund J, Sato A, Akira S, Medzhitov R, Iwasaki A. Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells. J Exp Med 2003; 198: 513-520.
32. Galen B, Cheshenko N, Tuyama A, Ramratnam B, Herold BC. Access to nectin favors herpes simplex virus infection at the apical surface of polarized human epithelial cells. J Virol 2006; 80: 12209-12218.
33. van Rijt LS, Jung S, Kleinjan A, Vos N, Willart M, Duez C et al. In vivo depletion of lung CD11c+ dendritic cells during allergen challenge abrogates the characteristic features of asthma. J Exp Med 2005; 201: 981-991.
34. Bogunovic M, Ginhoux F, Helft J, Shang L, Hashimoto D, Greter M et al. Origin of the lamina propria dendritic cell network. Immunity 2009; 31: 513-525.
35. Nakano H, Free ME, Whitehead GS, Maruoka S, Wilson RH, Nakano K et al. Pulmonary CD103(+) dendritic cells prime Th2 responses to inhaled allergens. Mucosal Immunol 2012; 5: 53-65.
36. Jaensson E, Uronen-Hansson H, Pabst O, Eksteen B, Tian J, Coombes JL et al. Small intestinal CD103+ dendritic cells display unique functional properties that are conserved between mice and humans. J Exp Med 2008; 205: 2139-2149.
37. Annacker O, Coombes JL, Malmstrom V, Uhlig HH, Bourne T, Johansson-Lindbom B et al. Essential role for CD103 in the T cell-mediated regulation of experimental colitis. J Exp Med 2005; 202: 1051-1061.
38. Mora JR, Iwata M, Eksteen B, Song SY, Junt T, Senman B et al. Generation of gut-homing IgA-secreting B cells by intestinal dendritic cells. Science 2006; 314: 1157-1160.
39. Worbs T, Bode U, Yan S, Hoffmann MW, Hintzen G, Bernhardt G et al. Oral tolerance originates in the intestinal immune system and relies on antigen carriage by dendritic cells. J Exp Med 2006; 203: 519-527.
40. Denning TL, Wang YC, Patel SR, Williams IR, Pulendran B. Lamina propria macrophages and dendritic cells differentially induce regulatory and interleukin 17-producing T cell responses. Nat Immunol 2007; 8: 1086-1094.
41. Guo B, Chang EY, Cheng G. The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. J Clin Invest 2008; 118: 1680-1690.
42. Zhang Z, Zheng M, Bindas J, Schwarzenberger P, Kolls JK. Critical role of IL-17 receptor signaling in acute TNBS-induced colitis. Inflamm Bowel Dis 2006; 12: 382-388.
43. Barbalat R, Lau L, Locksley RM, Barton GM. Toll-like receptor 2 on inflammatory monocytes induces type I interferon in response to viral but not bacterial ligands. Nat Immunol 2009; 10: 1200-1207.
44. Lee PY, Weinstein JS, Nacionales DC, Scumpia PO, Li Y, Butfiloski E et al. A novel type I IFN-producing cell subset in murine lupus. J Immunol 2008; 180: 5101-5108.
45. Rivollier A, He J, Kole A, Valatas V, Kelsall BL. Inflammation switches the differentiation program of Ly6Chi monocytes from antiinflammatory macrophages to inflammatory dendritic cells in the colon. J Exp Med 2012; 209: 139-155.
46. Chen Y, Chou K, Fuchs E, Havran WL, Boismenu R. Protection of the intestinal mucosa by intraepithelial gamma delta T cells. Proc Natl Acad Sci USA 2002; 99: 14338-14343.
47. Henry T, Kirimanjeswara GS, Ruby T, Jones JW, Peng K, Perret M et al. Type I IFN signaling constrains IL-17A/F secretion by gammadelta T cells during bacterial infections. J Immunol 2010; 184: 3755-3767.
48. Kunzmann V, Kretzschmar E, Herrmann T, Wilhelm M. Polyinosinic- polycytidylic acidmediated stimulation of human gammadelta T cells via CD11c dendritic cell-derived type I interferons. Immunology 2004; 112: 369-377.
49. Szretter KJ, Gangappa S, Belser JA, Zeng H, Chen H, Matsuoka Y et al. Early control of H5N1 influenza virus replication by the type I interferon response in mice. J Virol 2009; 83: 5825-5834.
50. Staeheli P, Grob R, Meier E, Sutcliffe JG, Haller O. Influenza virus-susceptible mice carry Mx genes with a large deletion or a nonsense mutation. Mol Cell Biol 1988; 8: 4518-4523.
51. Koerner I, Kochs G, Kalinke U, Weiss S, Staeheli P. Protective role of beta interferon in host defense against influenza A virus. J Virol 2007; 81: 2025-2030.
52. James CM, Abdad MY, Mansfield JP, Jacobsen HK, Vind AR, Stumbles PA et al. Differential activities of alpha/beta IFN subtypes against influenza virus in vivo and enhancement of specific immune responses in DNA vaccinated mice expressing haemagglutinin and nucleoprotein. Vaccine 2007; 25: 1856-1867.
53. Yoo JK, Baker DP, Fish EN. Interferon-beta modulates type 1 immunity during influenza virus infection. Antiviral Res 2010; 88: 64-71.
54. Gack MU, Albrecht RA, Urano T, Inn KS, Huang IC, Carnero E et al. Influenza A virus NS1 targets the ubiquitin ligase TRIM25 to evade recognition by the host viral RNA sensor RIG-I. Cell Host Microbe 2009; 5: 439-449.
55. Jia D, Rahbar R, Chan RW, Lee SM, Chan MC, Wang BX et al. Influenza virus nonstructural protein 1 (NS1) disrupts interferon signaling. PLoS One 2010; 5: e13927.
56. Ramaswamy M, Shi L, Varga SM, Barik S, Behlke MA, Look DC. Respiratory syncytial virus nonstructural protein 2 specifically inhibits type I interferon signal transduction. Virology 2006; 344: 328-339.
57. Bauer CM, Dewitte-Orr SJ, Hornby KR, Zavitz CC, Lichty BD, Stampfli MR et al. Cigarette smoke suppresses type I interferon-mediated antiviral immunity in lung fibroblast and epithelial cells. J Interferon Cytokine Res 2008; 28: 167-179.
58. Eddleston J, Lee RU, Doerner AM, Herschbach J, Zuraw BL. Cigarette smoke decreases innate responses of epithelial cells to rhinovirus infection. Am J Respir Cell MolBiol 2011; 44: 118-126.
59. HuangFu WC, Liu J, Harty RN, Fuchs SY. Cigarette smoking products suppress antiviral effects of Type I interferon via phosphorylation-dependent downregulation of its receptor. FEBS Lett 2008; 582: 3206-3210.
60. El-Zayadi A, Selim O, Hamdy H, El-Tawil A, Badran HM, Attia M et al. Impact of cigarette smoking on response to interferon therapy in chronic hepatitis C Egyptian patients. World J Gastroenterol 2004; 10: 2963-2966.
61. Kantarci O, Wingerchuk D. Epidemiology and natural history of multiple sclerosis: new insights. Curr Opin Neurol 2006; 19: 248-254.
62. Deonarain R, Alcami A, Alexiou M, Dallman MJ, Gewert DR, Porter AC. Impaired antiviral response and alpha/beta interferon induction in mice lacking beta interferon. J Virol 2000; 74: 3404-3409.
63. O'Connell RM, Saha SK, Vaidya SA, Bruhn KW, Miranda GA, Zarnegar B et al. Type I interferon production enhances susceptibility to Listeria monocytogenes infection. J Exp Med 2004; 200: 437-445.
64. Auerbuch V, Brockstedt DG, Meyer-Morse N, O'Riordan M, Portnoy DA. Mice lacking the type I interferon receptor are resistant to Listeria monocytogenes. J Exp Med 2004; 200: 527-533.
65. Nagarajan UM, Prantner D, Sikes JD, Andrews Jr. CW, Goodwin AM, Nagarajan S et al. Type I interferon signaling exacerbates Chlamydia muridarum genital infection in a murine model. Infect Immun 2008; 76: 4642-4648.
66. Stanley SA, Johndrow JE, Manzanillo P, Cox JS. The Type I IFN response to infection with Mycobacterium tuberculosis requires ESX-1-mediated secretion and contributes to pathogenesis. J Immunol 2007; 178: 3143-3152.
67. Carrero JA, Unanue ER. Lymphocyte apoptosis as an immune subversion strategy of microbial pathogens. Trends Immunol 2006; 27: 497-503.
68. Manca C, Tsenova L, Bergtold A, Freeman S, Tovey M, Musser JM et al. Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-αlpha/beta. Proc Natl Acad Sci USA 2001; 98: 5752-5757.
69. Antonelli LR, Gigliotti Rothfuchs A, Goncalves R, Roffe E, Cheever AW, Bafica A et al. Intranasal Poly-IC treatment exacerbates tuberculosis in mice through the pulmonary recruitment of a pathogen-permissive monocyte/macrophage population. J Clin Invest 2010; 120: 1674-1682.
70. Berry MP, Graham CM, McNab FW, Xu Z, Bloch SA, Oni T et al. An interferoninducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010; 466: 973-977.
71. Forster S. Interferon signatures and imune responses in disease. Immunol Cell Biol 2012; 90: 520-527.
72. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004; 118: 229-241.
73. McFarland AP, Savan R, Wagage S, Addison A, Ramakrishnan K, Karwan M et al. Localized delivery of interferon-beta by Lactobacillus exacerbates experimental colitis. PLoS One 2011; 6: e16967.
74. Weiss G, Rasmussen S, Zeuthen LH, Nielsen BN, Jarmer H, Jespersen L et al. Lactobacillus acidophilus induces virus immune defence genes in murine dendritic cells by a Toll-like receptor-2-dependent mechanism. Immunology 2010; 131: 268-281.
75. Mirpuri J, Brazil JC, Berardinelli AJ, Nasr TR, Cooper K, Schnoor M et al. Commensal Escherichia coli reduces epithelial apoptosis through IFN-αlphaA-mediated induction of guanylate binding protein-1 in human and murine models of developing intestine. J Immunol 2010; 184: 7186-7195.
76. Rachmilewitz D, Katakura K, Karmeli F, Hayashi T, Reinus C, Rudensky B et al. Tolllike receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 2004; 126: 520-528.
77. Shulzhenko N, Morgun A, Hsiao W, Battle M, Yao M, Gavrilova O et al. Crosstalk between B lymphocytes, microbiota and the intestinal epithelium governs immunity versus metabolism in the gut. Nat Med 2011; 17: 1585-1593.
78. Vijay-Kumar M, Aitken JD, Carvalho FA, Cullender TC, Mwangi S, Srinivasan S et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 2010; 328: 228-231.
79. Pena Rossi C, Hanauer SB, Tomasevic R, Hunter JO, Shafran I, Graffner H. Interferon beta-1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose-finding study. BMC Gastroenterol 2009; 9: 22.
80. Gasche C, Reinisch W, Vogelsang H, Potzi R, Markis E, Micksche M et al. Prospective evaluation of interferon-alpha in treatment of chronic active Crohn's disease. Dig Dis Sci 1995; 40: 800-804.
81. Pena-Rossi C, Schreiber S, Golubovic G, Mertz-Nielsen A, Panes J, Rachmilewitz D et al. Clinical trial: a multicentre, randomized, double-blind, placebo-controlled, dose-finding, phase II study of subcutaneous interferon-beta-la in moderately active ulcerative colitis. Aliment Pharmacol Ther 2008; 28: 758-767.
82. Sumer N, Palabiyikoglu M. Induction of remission by interferon-alpha in patients with chronic active ulcerative colitis. Eur J Gastroenterol Hepatol 1995; 7: 597-602.
83. Nguyen KB, Cousens LP, Doughty LA, Pien GC, Durbin JE, Biron CA. Interferon alpha/ beta-mediated inhibition and promotion of interferon gamma: STAT1 resolves a paradox. Nat Immunol 2000; 1: 70-76.
84. Kaser A, Molnar C, Tilg H. Differential regulation of interleukin 4 and interleukin 13 production by interferon alpha. Cytokine 1998; 10: 75-81.
85. Dickensheets HL, Venkataraman C, Schindler U, Donnelly RP. Interferons inhibit activation of STAT6 by interleukin 4 in human monocytes by inducing SOCS-1 gene expression. Proc Natl Acad Sci USA 1999; 96: 10800-10805.
86. Mannon PJ, Hornung RL, Yang Z, Yi C, Groden C, Friend J et al. Suppression of inflammation in ulcerative colitis by interferon-beta-1a is accompanied by inhibition of IL-13 production. Gut 2011; 60: 449-455.
87. Axtell RC, de Jong BA, Boniface K, van der Voort LF, Bhat R, De Sarno P et al. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med 2010; 16: 406-412.
88. Moschen AR, Geiger S, Krehan I, Kaser A, Tilg H. Interferon-alpha controls IL-17 expression in vitro and in vivo. Immunobiology 2008; 213: 779-787.
89. Kalinke U, Prinz M. Endogenous, or therapeutically induced, tyoe I interferon responses differentially modulate Th1/Th17-mediated autoimmunity in the CNS. Imunol Cell Biol 2012; 90: 505-509.
90. Spencer TE, Ott TL, Bazer FW. tau-Interferon: pregnancy recognition signal in ruminants. Proc Soc Exp Biol Med 1996; 213: 215-229.
91. Lefevre F, Guillomot M, D'Andrea S, Battegay S, La Bonnardiere C. Interferon-delta: the first member of a novel type I interferon family. Biochimie 1998; 80: 779-788.
92. Hardy MP, Owczarek CM, Jermiin LS, Ejdeback M, Hertzog PJ. Characterization of the type I interferon locus and identification of novel genes. Genomics 2004; 84: 331-345.
93. Sharkey DJ, Macpherson AM, Tremellen KP, Robertson SA. Seminal plasma differentially regulates inflammatory cytokine gene expression in human cervical and vaginal epithelial cells. Mol Hum Reprod 2007; 13: 491-501.
94. Fidel Jr PL. History and update on host defense against vaginal candidiasis. Am J Reprod Immunol 2007; 57: 2-12.
95. WHO Global Prevalence and Incidence of Selected Curable Sexually Transmitted Infections: Overview and Estimates. WHO, Geneva, Switzerland, 2005.
96. Svensson A, Bellner L, Magnusson M, Eriksson K. Role of IFN-αlpha/beta signaling in the prevention of genital herpes virus type 2 infection. J Reprod Immunol 2007; 74: 114-123.
97. Pasieka TJ, Lu B, Leib DA. Enhanced pathogenesis of an attenuated herpes simplex virus for mice lacking Stat1. J Virol 2008; 82: 6052-6055.
98. Harle P, Noisakran S, Carr DJ. The application of a plasmid DNA encoding IFN-alpha 1 postinfection enhances cumulative survival of herpes simplex virus type 2 vaginally infected mice. J Immunol 2001; 166: 1803-1812.
99. Austin BA, James CM, Harle P, Carr DJ. Direct application of plasmid DNA containing type I interferon transgenes to vaginal mucosa inhibits HSV-2 mediated mortality. Biol Proced Online 2006; 8: 55-62.
100. Thapa M, Welner RS, Pelayo R, Carr DJ. CXCL10 expression are critical for control of genital herpes simplex virus type 2 infection through mobilization of HSV-specific CTL and NK cells to the nervous system. J Immunol 2008; 180: 1098-1106.
101. Moffett-King A. Natural killer cells and pregnancy. Nat Rev Immunol 2002; 2: 656-663.
102. Al-Khatib K, Williams BR, Silverman RH, Halford W, Carr DJ. Distinctive roles for 20,50-oligoadenylate synthetases and double-stranded RNA-dependent protein kinase R in the in vivo antiviral effect of an adenoviral vector expressing murine IFN-βeta. J Immunol 2004; 172: 5638-5647.
103. Zheng X, Silverman RH, Zhou A, Goto T, Kwon BS, Kaufman HE et al. Increased severity of HSV-1 keratitis and mortality in mice lacking the 2-5 A-dependent RNase L gene. Invest Ophthalmol Vis Sci 2001; 42: 120-126.
104. Khabar KS, Dhalla M, Siddiqui Y, Zhou A, Al-Ahdal MN, Der SD et al. Effect of deficiency of the double-stranded RNA-dependent protein kinase, PKR, on antiviral resistance in the presence or absence of ribonuclease L: HSV-1 replication is particularly sensitive to deficiency of the major IFN-mediated enzymes. J Interferon Cytokine Res 2000; 20: 653-659.
105. Leib DA, Machalek MA, Williams BR, Silverman RH, Virgin HW. Specific phenotypic restoration of an attenuated virus by knockout of a host resistance gene. Proc Natl Acad Sci USA 2000; 97: 6097-6101.
106. Carr DJ, Tomanek L, Silverman RH, Campbell IL, Williams BR. RNA-dependent protein kinase is required for alpha-1 interferon transgene-induced resistance to genital herpes simplex virus type 2. J Virol 2005; 79: 9341-9345.
107. Lenschow DJ, Lai C, Frias-Staheli N, Giannakopoulos NV, Lutz A, Wolff T et al. IFN-stimulated gene 15 functions as a critical antiviral molecule against influenza, herpes, and Sindbis viruses. Proc Natl Acad Sci USA 2007; 104: 1371-1376.
108. Melroe GT, Silva L, Schaffer PA, Knipe DM. Recruitment of activated IRF-3 and CBP/ p300 to herpes simplex virus ICP0 nuclear foci: potential role in blocking IFN-βeta induction. Virology 2007; 360: 305-321.
109. Johnson KE, Knipe DM. Herpes simplex virus-1 infection causes the secretion of a type I interferon-antagonizing protein and inhibits signaling at or before Jak-1 activation. Virology 2010; 396: 21-29.
110. UNAIDS: Report on AIDS Epidemic 2008
111. Schneider T, Jahn HU, Schmidt W, Riecken EO, Zeitz M, Ullrich R. Loss of CD4 T lymphocytes in patients infected with human immunodeficiency virus type 1 is more pronounced in the duodenal mucosa than in the peripheral blood. Berlin Diarrhea/Wasting Syndrome Study Group. Gut 1995; 37: 524-529.
112. Haase AT. Perils at mucosal front lines for HIV and SIV and their hosts. Nat Rev Immunol 2005; 5: 783-792.
113. Li Q, Smith AJ, Schacker TW, Carlis JV, Duan L, Reilly CS et al. Microarray analysis of lymphatic tissue reveals stage-specific, gene expression signatures in HIV-1 infection. J Immunol 2009; 183: 1975-1982.
114. Li Q, Estes JD, Schlievert PM, Duan L, Brosnahan AJ, Southern PJ et al. Glycerol monolaurate prevents mucosal SIV transmission. Nature 2009; 458: 1034-1038.
115. Ozato K, Shin DM, Chang TH, Morse 3rd HC. TRIM family proteins and their emerging roles in innate immunity. Nat Rev Immunol 2008; 8: 849-860.
116. Okumura A, Lu G, Pitha-Rowe I, Pitha PM. Innate antiviral response targets HIV-1 release by the induction of ubiquitin-like protein ISG15. Proc Natl Acad Sci USA 2006; 103: 1440-1445.
117. Espert L, Degols G, Lin YL, Vincent T, Benkirane M, Mechti N. Interferon-induced exonuclease ISG20 exhibits an antiviral activity against human immunodeficiency virus type 1. J Gen Virol 2005; 86(Pt 8): 2221-2229.
118. Doehle BP, Hladik F, McNevin JP, McElrath MJ, Gale Jr M. Human immunodeficiency virus type 1 mediates global disruption of innate antiviral signaling and immune defenses within infected cells. J Virol 2009; 83: 10395-10405.
119. Vendrame D, Sourisseau M, Perrin V, Schwartz O, Mammano F. Partial inhibition of human immunodeficiency virus replication by type I interferons: impact of cell-to-cell viral transfer. J Virol 2009; 83: 10527-10537.
120. Harman AN, Lai J, Turville S, Samarajiwa S, Gray L, Marsden V et al. HIV infection of dendritic cells subverts the IFN induction pathway via IRF-1 and inhibits type 1 IFN production. Blood 2011; 118: 298-308.
121. Zhu J, Hladik F, Woodward A, Klock A, Peng T, Johnston C et al. Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat Med 2009; 15: 886-892.
122. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006; 20: 73-83.
123. Morrison RP, Caldwell HD. Immunity to murine chlamydial genital infection. Infect Immun 2002; 70: 2741-2751.
124. Nagarajan UM, Ojcius DM, Stahl L, Rank RG, Darville T. Chlamydia trachomatis induces expression of IFN-gamma-inducible protein 10 and IFN-βeta independent of TLR2 and TLR4, but largely dependent on MyD88. J Immunol 2005; 175: 450-460.
125. Johnson RM. Murine oviduct epithelial cell cytokine responses to Chlamydia muridarum infection include interleukin-12-p70 secretion. Infect Immun 2004; 72: 3951-3960.
126. Lad SP, Fukuda EY, Li J, de la Maza LM, Li E. Up-regulation of the JAK/STAT1 signal pathway during Chlamydia trachomatis infection. J Immunol 2005; 174: 7186-7193.
127. Ren Q, Robertson SJ, Howe D, Barrows LF, Heinzen RA. Comparative DNA microarray analysis of host cell transcriptional responses to infection by Coxiella burnetii or Chlamydia trachomatis. Ann N Y Acad Sci 2003; 990: 701-713.
128. Howard J. The IRG proteins: a function in search of a mechanism. Immunobiology 2008; 213: 367-375.
129. Le Bon A, Schiavoni G, D'Agostino G, Gresser I, Belardelli F, Tough DF. Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 2001; 14: 461-470.
130. Tovey MG, Lallemand C, Meritet JF, Maury C. Adjuvant activity of interferon alpha: mechanism(s) of action. Vaccine 2006; 24(Suppl 2): S2-46-7.
131. Bracci L, Canini I, Venditti M, Spada M, Puzelli S, Donatelli I et al. Type I IFN as a vaccine adjuvant for both systemic and mucosal vaccination against influenza virus. Vaccine 2006; 24(Suppl 2): S2-56-7.
132. Shen H, Iwasaki A. A crucial role for plasmacytoid dendritic cells in antiviral protection by CpG ODN-based vaginal microbicide. J Clin Invest 2006; 116: 2237-2243.
133. Harandi AM, Eriksson K, Holmgren J. A protective role of locally administered immunostimulatory CpG oligodeoxynucleotide in a mouse model of genital herpes infection. J Virol 2003; 77: 953-962.
134. Herbst-Kralovetz MM, Pyles RB. Quantification of poly(I:C)-mediated protection against genital herpes simplex virus type 2 infection. J Virol 2006; 80: 9988-9997.
135. Pal R, Venzon D, Santra S, Kalyanaraman VS, Montefiori DC, Hocker L et al. Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simianhuman immunodeficiency virus SHIVKU2 RNA levels. J Virol 2006; 80: 3732-3742.
136. Alsharifi M, Furuya Y, Bowden TR, Lobigs M, Koskinen A, Regner M et al. Intranasal flu vaccine protective against seasonal and H5N1 avian influenza infections. PLoS One 2009; 4: e5336.
137. Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol 2006; 12: 4819-4831.
138. Samson M, Audia S, Duchene C, Perinet I, Bielefeld P, Besancenot JF. Crohn's disease during the course of multiple sclerosis: role of interferon-beta therapy. Rev Med Interne 2009; 30: 816-819.
139. Sprenger R, Sagmeister M, Offner F. Acute ulcerative colitis during successful interferon/ ribavirin treatment for chronic hepatitis. Gut 2005; 54: 438-439. author reply 439.